These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33464703)

  • 1. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
    Harreiter J; Just I; Leutner M; Bastian M; Brath H; Schelkshorn C; Klepochova R; Krššák M; Kautzky-Willer A
    Diabetes Obes Metab; 2021 May; 23(5):1129-1139. PubMed ID: 33464703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Frías JP; Maaske J; Suchower L; Johansson L; Hockings PD; Iqbal N; Wilding JPH
    Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK; Choi KM; Han KA; Kim KA; Kim IJ; Han SJ; Lee WY; Yoo SJ
    Diabetes Obes Metab; 2024 Nov; 26(11):5065-5077. PubMed ID: 39223856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
    Gastaldelli A; Repetto E; Guja C; Hardy E; Han J; Jabbour SA; Ferrannini E
    Diabetes Obes Metab; 2020 Mar; 22(3):393-403. PubMed ID: 31692226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
    Han KA; Hwang YC; Moon SJ; Cho HC; Yoo HJ; Choi SH; Chon S; Kim KA; Kim TN; Kang JG; Park CY; Won JC; Cho E; Kim J; Park KS
    Diabetes Obes Metab; 2024 Sep; 26(9):3743-3752. PubMed ID: 38978173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
    Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Frías JP; Hardy E; Ahmed A; Öhman P; Jabbour S; Wang H; Guja C
    Diabetes Obes Metab; 2018 Jun; 20(6):1520-1525. PubMed ID: 29573139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T; Ekholm E; Johnsson E; Garcia-Sanchez R; Dronamraju N; Jabbour SA; Lind M
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
    Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
    Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A
    Brown E; Wilton MM; Sprung VS; Harrold JA; Halford JCG; Stancak A; Burgess M; Howarth E; Umpleby AM; Kemp GJ; Wilding JP; Cuthbertson DJ
    BMJ Open; 2021 Jul; 11(7):e045663. PubMed ID: 34285005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA; Frías JP; Ahmed A; Hardy E; Choi J; Sjöström CD; Guja C
    Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
    Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.